查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081988

疫苗契約製造市場：2026-2032年全球市場預測（按疫苗類型、技術平台、服務內容、應用領域、應用階段和最終用戶分類）

Vaccine Contract Manufacturing Market by Vaccine Type, Technology Platform, Service Offering, Application Type, Application Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，疫苗契約製造市場將成長至 114.3 億美元，複合年成長率為 9.53%。

主要市場統計數據
基準年 2025 60.4億美元
預計年份：2026年 65.6億美元
預測年份：2032年 114.3億美元
複合年成長率 (%) 9.53%

疫苗契約製造市場正經歷變革，這主要得益於對靈活生產能力、快速技術轉移、符合監管標準的品管體係以及穩健的全球供應鏈的需求。疫苗研發企業越來越依賴合約研發生產機構（CDMO）來生產原料藥成分、填充和包裝、分析檢測、包裝、低溫運輸減毒活病毒疫苗，以及在mRNA、重組蛋白、病毒載體、結合疫苗、去活化疫苗和減毒活疫苗等多種疫苗平台上實現商業化規模生產。

本執行摘要契約製造定位為一項戰略性衛生安全基礎設施，而不僅僅是基於交易的外包類別。世界衛生組織 (WHO)、流行病防範創新聯盟 (CEPI)、全球疫苗免疫聯盟 (Gavi) 和聯合國兒童基金會 (UNICEF) 的採購系統，以及各國衛生機構和包括美國食品藥物管理局(FDA)和歐洲藥品管理局 (EMA) 在內的嚴格監管機構所確認的優先事項如今已成為生物疫苗製造的優先事項、免疫接種、法律和疫苗生產的優先事項

疫苗生產格局的變革性變化

產業趨勢正從單一平台、以宣傳活動為導向的疫苗生產模式轉向模組化、多平台的生產網路。每種技術——mRNA、重組蛋白、病毒載體、偶聯物和去活化疫苗——在上游和下游製程、無菌填充和包裝、無菌保證以及品管方面都需要不同的能力。因此，研發公司正在尋求與合約研發生產機構（CDMO）建立合作關係，以便管理整個平台和生命週期各個階段的複雜性。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過改進製程開發、預測性維護、偏差管理、需求計劃、原料風險監控和批次放行分析，在契約製造的整體都帶來了累積的益處。在受監管的 GMP 環境中，當 AI 與經過驗證的資料系統、人工監督、審計追蹤、網路安全措施以及品質源自設計 (QbD) 原則相結合時，其價值將得以最大程度地發揮。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區是契約製造的關鍵樞紐，這得益於印度和中國大規模的生產能力、日本和韓國先進的生物製造技術，以及澳洲和東南亞國內生產能力的擴張。印度擁有許多大型疫苗生產商，並長期參與全球免疫供應，包括聯合國兒童基金會和全球疫苗免疫聯盟（Gavi）支持的供應管道，這些都增強了印度的角色。同時，韓國和日本繼續投資生物製藥、mRNA、病毒載體以及灌裝包裝基礎設施。澳洲和東協市場正透過國內生產計畫、監理間合作和低溫運輸現代化來提升自身能力。

主要區域分析：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

在東協，隨著成員國減少對進口疫苗的依賴並加強應對感染疾病疫情的能力，監管合作、低溫運輸系統和生物製藥投資變得日益重要。海灣合作理事會（GCC）利用醫療衛生在地化策略、採購措施、政府投資和產業多元化，吸引灌裝和精加工、包裝、品管以及生物製藥製造領域的夥伴關係，以符合國家衛生安全目標。

對主要疫苗契約製造市場關鍵國家的洞察

美國憑藉先進的研發能力、符合FDA規範的GMP生產、BARDA支持的疫情應對準備以及強大的CDMO基礎設施（涵蓋NIH支持的疫苗科學、原料藥、灌裝和包裝、分析測試以及低溫運輸物流），在行業中處於領先地位。加拿大正透過國家級生命科學和疫情應對計畫重建其國內生物製造能力。同時，墨西哥受益於其接近性北美供應鏈的地理優勢、區域貿易整合以及不斷擴大的醫療保健製造能力。巴西憑藉其完善的公共部門機構和技術轉移經驗，成為拉丁美洲主要的疫苗生產市場。英國也在生命科學創新、臨床開發、監管能力和疫苗平台研究方面繼續發揮重要作用。

為行業領導者提供的實用建議

行業領導者應優先考慮平台柔軟性、檢驗的技術轉移以及強大的供應商網路。能夠處理多種疫苗劑型、管理GMP文件並提供原料藥、填充和包裝、檢測、貼標、序列化和低溫運輸服務等一體化服務的CDMO，更有可能滿足商業項目、臨床試驗和緊急應變的需求。

調查方法

本調查方法基於二手研究框架，利用檢驗的公共資訊來源，包括世界衛生組織、監管機構、政府緊急應變計畫、公共採購參考資料、科學文獻和認可的行業舉措。分析重點關注來自世衛組織、流行病防範創新聯盟（CEPI）、全球疫苗免疫聯盟（Gavi）、聯合國兒童基金會採購實踐、美國食品藥品監督管理局（FDA）、歐洲藥品管理局（EMA）、非洲疾病預防控制中心（Africa CDC）、泛美衛生組織（PAHO）、國家免疫規劃和政府支持的生物製造計畫的證據。

結論

疫苗契約製造正成為全球衛生安全、常規免疫和生物製藥競爭力的核心支柱。最大的機會正湧現於各種技術平台、監管合規、區域准入、供應鏈韌性和檢驗的品質基礎設施的交匯點。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：疫苗契約製造：依疫苗類型分類

  • DNA
  • 失活
  • 減毒活病毒疫苗
  • mRNA
  • 類毒素
  • 病毒載體

第8章：疫苗契約製造市場：依技術平台分類

  • 基於細胞
    • 黏附培養
    • 懸浮培養
  • 自給自足
  • 蛋製品
  • 合成胜肽

第9章：疫苗契約製造市場：依所提供的服務分類

  • 分析服務
  • 原料藥生產
  • 填充和精加工
  • 藥學服務
  • 物流
  • 包裝

第10章：疫苗契約製造市場：依應用領域分類

  • 預防性疫苗
  • 治療性疫苗

第11章：疫苗契約製造市場：依應用階段分類

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業階段

第12章：疫苗契約製造市場：依最終用戶分類

  • 生技公司
  • 政府機構
  • 製藥公司

第13章：疫苗契約製造市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：疫苗契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：疫苗契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc
  • Ajinomoto Co., Inc.
  • Alcami Corporation, Inc.
  • Aton（Shanghai）BIoTech Co., Ltd.
  • Avid Bioservices, Inc.
  • Batavia Biosciences BV
  • BioReliance Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Cobra Biologics Limited
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics（Shenzhen Hepalink Pharmaceutical Group Co., Ltd.）
  • Emergent BioSolutions Inc.
  • Eurogentec SA
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.（FUJIFILM Corporation）
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • Grand River Aseptic Manufacturing, Inc.
  • HIPRA Human Health, SLU
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Laboratorios Farmaceuticos Rovi, SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Ology Bioservices, Inc.
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Pharmaceutical Product Development（Thermo Fisher Scientific Inc.）
  • Piramal Pharma Limited
  • Recipharm AB
  • Serum Institute of India
  • Toyobo Co., Ltd.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi AppTec Co., Ltd.
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market is projected to grow by USD 11.43 billion at a CAGR of 9.53% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.04 billion
Estimated Year [2026] USD 6.56 billion
Forecast Year [2032] USD 11.43 billion
CAGR (%) 9.53%

The vaccine contract manufacturing market is being reshaped by demand for flexible capacity, faster technology transfer, regulatory-grade quality systems, and resilient global supply chains. Vaccine developers increasingly rely on contract development and manufacturing organizations (CDMOs) for drug substance production, fill-finish operations, analytical testing, packaging, cold-chain readiness, and commercial scale-up across mRNA, recombinant protein, viral vector, conjugate, inactivated, and live-attenuated vaccine platforms.

The executive summary frames vaccine contract manufacturing as strategic health security infrastructure rather than a transactional outsourcing category. Verified priorities from the World Health Organization, CEPI, Gavi, UNICEF procurement systems, national health agencies, and stringent regulators including the U.S. FDA and European Medicines Agency show that pandemic preparedness, routine immunization, equitable access, and localized vaccine production are now central to long-term biomanufacturing investment and partnership decisions.

Transformative Shifts in the Vaccine Manufacturing Landscape

The landscape is shifting from single-platform, campaign-based vaccine production toward modular, multi-platform manufacturing networks. mRNA, recombinant protein, viral vector, conjugate, and inactivated vaccine technologies require differentiated upstream, downstream, aseptic fill-finish, sterility assurance, and quality-control capabilities, encouraging developers to partner with CDMOs that can manage complexity across platforms and lifecycle stages.

Another major shift is the regionalization of capacity. Governments are using procurement, public-private partnerships, national stockpiling, and biosecurity policies to reduce reliance on concentrated supply chains. At the same time, regulators are emphasizing data integrity, GMP compliance, pharmacovigilance readiness, and robust comparability packages, making proven tech transfer, validation, batch documentation, and regulatory submission support core differentiators for vaccine manufacturing partners.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative gains across vaccine contract manufacturing by improving process development, predictive maintenance, deviation management, demand planning, raw-material risk monitoring, and batch-release analytics. In regulated GMP environments, AI is most valuable when paired with validated data systems, human oversight, audit trails, cybersecurity controls, and quality-by-design principles.

For CDMOs, AI can shorten development cycles by identifying critical process parameters earlier, supporting digital twins for scale-up, and detecting quality trends before they become failures. The impact is cumulative because each validated data set strengthens future campaigns, improving manufacturing reliability, capacity utilization, technology transfer consistency, and client confidence without replacing regulatory accountability or qualified person oversight where required.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a critical hub for vaccine contract manufacturing due to large-scale capacity in India and China, advanced biomanufacturing in Japan and South Korea, and growing sovereign capacity in Australia and Southeast Asia. India's role is reinforced by high-volume vaccine producers and its long-standing participation in global immunization supply, including UNICEF and Gavi-supported channels, while South Korea and Japan continue to invest in biologics, mRNA, viral vector, and fill-finish infrastructure. Australia and ASEAN markets are strengthening preparedness through domestic manufacturing programs, regulatory cooperation, and cold-chain modernization.

North America remains anchored by the United States and Canada, where BARDA, NIH, Health Canada, and FDA-regulated manufacturing ecosystems support advanced vaccine development, emergency preparedness, GMP compliance, and public-private capacity programs. Latin America is strengthened by Brazil's established public vaccine institutions, Mexico's proximity to North American supply chains, and PAHO-supported regional health cooperation, which together support technology transfer, fill-finish expansion, and regional immunization resilience.

Europe benefits from EMA standards, the European Health Emergency Preparedness and Response Authority, coordinated procurement experience, and strong CDMO clusters in Germany, France, Italy, Spain, and the United Kingdom. The Middle East is investing in localization through healthcare diversification agendas, especially across Gulf economies seeking biologics, packaging, and fill-finish capabilities. Africa is gaining momentum through the African Union and Africa CDC's Partnerships for African Vaccine Manufacturing, which targets expanded continental vaccine production by 2040 and supports a shift from import dependence toward sustainable regional manufacturing.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is increasingly relevant as member states strengthen regulatory cooperation, cold-chain systems, and biopharmaceutical investment to reduce dependence on imported vaccines and improve outbreak-response readiness. The GCC is using healthcare localization strategies, procurement policy, sovereign investment, and industrial diversification to attract fill-finish, packaging, quality-control, and biologics manufacturing partnerships aligned with national health security goals.

The European Union plays a central role through EMA-aligned regulatory oversight, HERA preparedness planning, coordinated funding for health resilience, and cross-border mechanisms that support vaccine availability during public health emergencies. BRICS countries add manufacturing depth through China, India, Brazil, Russia, and South Africa, combining large domestic immunization requirements with expanding vaccine production capacity, technology transfer initiatives, and public-sector immunization programs.

The G7 influences vaccine contract manufacturing through financing, innovation policy, global health commitments, pandemic preparedness initiatives, and regulatory convergence among high-income markets. NATO is not a vaccine regulator, but its focus on resilience, civil preparedness, logistics, and medical countermeasures reinforces the strategic importance of secure vaccine supply chains, protected manufacturing infrastructure, and reliable access to critical biologics during crises.

Key Country Insights Across Major Vaccine Contract Manufacturing Markets

The United States leads through advanced R&D, FDA-regulated GMP manufacturing, BARDA-supported preparedness, NIH-backed vaccine science, and a deep CDMO base spanning drug substance, fill-finish, analytical testing, and cold-chain logistics. Canada is rebuilding domestic biomanufacturing capacity through national life sciences and pandemic preparedness programs, while Mexico benefits from proximity to North American supply chains, regional trade integration, and growing healthcare manufacturing capabilities. Brazil is Latin America's key vaccine manufacturing market through established public-sector institutions and technology transfer experience, and the United Kingdom remains important for life sciences innovation, clinical development, regulatory capability, and vaccine platform research.

In Europe, Germany, France, Italy, and Spain provide strong biologics, aseptic manufacturing, quality-system expertise, and EMA-aligned regulatory experience, while Russia maintains domestic vaccine production capacity and a public-sector focus on self-sufficiency. In Asia-Pacific, China and India offer scale across vaccine production, supplier ecosystems, and domestic immunization demand, with India especially important for global dose supply and established participation in international procurement channels. Japan, Australia, and South Korea add high-quality manufacturing, government-backed preparedness, advanced biologics capabilities, and growing interest in mRNA, recombinant protein, and next-generation vaccine technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platform flexibility, validated tech transfer, and resilient supplier networks. CDMOs that can support multiple vaccine modalities, manage GMP documentation, and provide integrated drug substance, fill-finish, testing, labeling, serialization, and cold-chain services will be better positioned for commercial programs, clinical pipelines, and emergency-response demand.

Firms should also invest in digital quality systems, AI-enabled process monitoring, dual sourcing, workforce training, and regional manufacturing partnerships. Strategic success depends on aligning capacity expansion with regulator expectations, public-sector procurement priorities, biosafety requirements, cold-chain specifications, and client demand for speed without compromising safety, potency, sterility, traceability, or compliance.

Research Methodology

Research methodology is developed using a secondary-research framework grounded in verified public-domain sources, including international health agencies, regulatory authorities, government preparedness programs, public procurement references, scientific literature, and recognized industry bodies. The analysis emphasizes evidence from WHO, CEPI, Gavi, UNICEF procurement practices, FDA, EMA, Africa CDC, PAHO, national immunization programs, and government-backed biomanufacturing initiatives.

The methodology avoids unsupported market sizing claims and prioritizes traceable indicators such as regulatory policy, manufacturing investments, platform adoption, public-private partnerships, capacity-building programs, localization strategies, technology transfer activity, and quality-system requirements. Insights are synthesized to identify structural trends in vaccine contract manufacturing without presenting market estimation, market share, or market forecasting.

Conclusion

Vaccine contract manufacturing is becoming a core pillar of global health security, routine immunization, and biopharmaceutical competitiveness. The strongest opportunities are emerging where technical platform breadth, regulatory compliance, regional access, supply-chain resilience, and verified quality infrastructure intersect.

As vaccine pipelines diversify and governments strengthen preparedness systems, CDMOs with validated quality infrastructure, scalable capacity, digital manufacturing capabilities, and proven tech transfer models will command strategic value. The market's long-term direction is clear: faster, more distributed, more compliant, more resilient, and increasingly data-driven vaccine manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vaccine Contract Manufacturing Market, by Vaccine Type

  • 7.1. DNA
  • 7.2. Inactivated
  • 7.3. Live Attenuated
  • 7.4. MRNA
  • 7.5. Toxoid
  • 7.6. Viral Vector

8. Vaccine Contract Manufacturing Market, by Technology Platform

  • 8.1. Cell Based
    • 8.1.1. Adherent Cell Culture
    • 8.1.2. Suspension Cell Culture
  • 8.2. Cell Free
  • 8.3. Egg Based
  • 8.4. Synthetic Peptide

9. Vaccine Contract Manufacturing Market, by Service Offering

  • 9.1. Analytical Services
  • 9.2. Drug Substance Manufacturing
  • 9.3. Fill Finish
  • 9.4. Formulation Services
  • 9.5. Logistics
  • 9.6. Packaging

10. Vaccine Contract Manufacturing Market, by Application Type

  • 10.1. Preventive Vaccines
  • 10.2. Therapeutic Vaccines

11. Vaccine Contract Manufacturing Market, by Application Stage

  • 11.1. Clinical Stage
    • 11.1.1. Phase I
    • 11.1.2. Phase Ii
    • 11.1.3. Phase Iii
  • 11.2. Commercial Stage

12. Vaccine Contract Manufacturing Market, by End User

  • 12.1. Biotech Companies
  • 12.2. Government Agencies
  • 12.3. Pharmaceutical Companies

13. Vaccine Contract Manufacturing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Vaccine Contract Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vaccine Contract Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc
  • 17.2. Ajinomoto Co., Inc.
  • 17.3. Alcami Corporation, Inc.
  • 17.4. Aton (Shanghai) Biotech Co., Ltd.
  • 17.5. Avid Bioservices, Inc.
  • 17.6. Batavia Biosciences B.V.
  • 17.7. BioReliance Corporation
  • 17.8. Catalent, Inc.
  • 17.9. Charles River Laboratories International, Inc.
  • 17.10. Cobra Biologics Limited
  • 17.11. CSL Limited
  • 17.12. Curia Global, Inc.
  • 17.13. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 17.14. Emergent BioSolutions Inc.
  • 17.15. Eurogentec S.A.
  • 17.16. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 17.17. Gedeon Richter PLC
  • 17.18. GlaxoSmithKline PLC
  • 17.19. Grand River Aseptic Manufacturing, Inc.
  • 17.20. HIPRA Human Health, S.L.U.
  • 17.21. ICON PLC
  • 17.22. IDT Biologika GmbH
  • 17.23. KBI Biopharma, Inc. by JSR Corporation
  • 17.24. Klocke Pharma-Service GmbH
  • 17.25. Laboratorios Farmaceuticos Rovi, S.A.
  • 17.26. Lonza Group Ltd.
  • 17.27. Merck KGaA
  • 17.28. Moderna, Inc.
  • 17.29. Ology Bioservices, Inc.
  • 17.30. Oxford Biomedica plc
  • 17.31. Pfizer Inc.
  • 17.32. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 17.33. Piramal Pharma Limited
  • 17.34. Recipharm AB
  • 17.35. Serum Institute of India
  • 17.36. Toyobo Co., Ltd.
  • 17.37. Vetter Pharma-Fertigung GmbH & Co. KG
  • 17.38. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL FREE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL FREE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL FREE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EGG BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EGG BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EGG BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FILL FINISH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FILL FINISH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FILL FINISH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FORMULATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FORMULATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FORMULATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CLINICAL STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CLINICAL STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CLINICAL STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 160. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 161. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 162. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 188. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 189. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 196. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 197. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 198. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 324. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 333. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 334. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA